> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Pacira Withdraws 2026 Guidance And Skips Earnings Call While Viatris' $36.50 Offer Runs
- URL: https://www.bullished.co/pacira-withdraws-2026-guidance-and-skips-earnings-call-while-viatris-36-50-offer-runs-781a55b2/
- Published: 2026-11-06T12:41:04.000Z
- Updated: 2026-11-06T12:41:04.000Z
- Description: Pacira will issue no third-quarter results and no outlook updates while Viatris' $36.50-a-share cash tender offer is pending.
- Author: Matteo Parrino
- Tags: Deals, PCRX, Industry: Healthcare

[Pacira BioSciences](https://www.bullished.co/tag/pcrx/), which makes non-opioid pain treatments, said in an [8-K filed Thursday](https://www.sec.gov/Archives/edgar/data/0001396814/000162828026071129/pcrx-20261105.htm?ref=bullished.co) that it will release no third-quarter earnings and hold no call, and it is pulling its 2026 financial guidance. The reason is Viatris' pending tender offer of $36.50 per share in cash.

## No numbers while the offer is open

Pacira will not issue an earnings release for the quarter ended September 30, 2026, and will not hold a conference call on its results. It is also withdrawing the 2026 financial guidance it issued earlier and will not update it while the offer and merger are pending.

Shares closed at $36.42 on Thursday, before the filing was accepted at 4:33 p.m. ET, just under the [$36.50 offer price](https://markets.ft.com/data/announce/full?dockey=600-202610300840PR%5FNEWS%5FUSPRX%5F%5F%5F%5FNE85051-1&ref=bullished.co).

## How the Viatris deal works

Under a merger agreement signed October 8, Viatris subsidiary Peach Purchaser Sub [launched a tender offer](https://markets.ft.com/data/announce/full?dockey=600-202610300840PR%5FNEWS%5FUSPRX%5F%5F%5F%5FNE85051-1&ref=bullished.co) on October 30 for all outstanding Pacira shares at $36.50 each in cash. Viatris said Pacira's board unanimously recommends that stockholders tender.

Once the offer is completed, the purchaser will merge into Pacira under Section 251(h) of Delaware law, leaving Pacira a wholly owned Viatris subsidiary. That route needs no Pacira stockholder vote, and tendered shares can be withdrawn until the offer expires.

## What Pacira sells

Pacira's three commercial products are EXPAREL, a long-acting local anesthetic injection for postsurgical pain; ZILRETTA, an extended-release steroid injection for osteoarthritis knee pain; and iovera, a handheld device that uses cold to treat a targeted nerve. In 2025, EXPAREL sales were $575.1 million, or 79% of total revenues, ZILRETTA sales were $116.6 million and iovera sales were $24.2 million, according to its annual report.

The company is also developing PCRX-201, a gene therapy in mid-stage trials for knee osteoarthritis.

The offer expires November 16 unless Viatris extends it, and any extension must be announced by 9 a.m. ET the next business day.

Learn

- [Item 7.01: Regulation FD disclosure →](https://www.bullished.co/learn/8-k-items-explained/#item-701-regulation-fd-disclosure)  
From 8-K Items Explained: What Every Item Code From 1.01 To 9.01 Tells You, With Examples

### Sources

- [8-K Filing — Pacira BioSciences, Inc. (PCRX)](https://www.sec.gov/Archives/edgar/data/0001396814/000162828026071129/pcrx-20261105.htm?ref=bullished.co) — SEC EDGAR
- [Viatris Announces Commencement of Tender Offer to Acquire Pacira BioSciences, Inc. – Company Announcement - FT.com](https://markets.ft.com/data/announce/full?dockey=600-202610300840PR%5FNEWS%5FUSPRX%5F%5F%5F%5FNE85051-1&ref=bullished.co) — Financial Times

### More on Pacira BioSciences

- [Pacira Board Urges Holders To Take Viatris's $36.50 Cash, Up From $31.00 Opening Bid](https://www.bullished.co/pacira-board-urges-holders-to-take-viatriss-36-50-cash-up-from-31-00-opening-bid-43664943/)
- [Viatris Starts $36.50-A-Share Cash Tender Offer For Pacira, A Few Cents Above Its Last Close](https://www.bullished.co/viatris-starts-36-50-a-share-cash-tender-offer-for-pacira-a-few-cents-above-its-last-close-68747ece/)
- [Doma Perpetual Sold 2,936,794 Pacira Shares And Now Reports Owning None](https://www.bullished.co/doma-perpetual-sold-2-936-794-pacira-shares-and-now-reports-owning-none-28754ee2/)

[All Pacira BioSciences (PCRX) coverage →](https://www.bullished.co/tag/pcrx/)